Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States

Arthritis Rheumatol. 2020 Jun;72(6):1036-1038. doi: 10.1002/art.41201. Epub 2020 Apr 7.

Authors

Seoyoung C Kim¹, Ameet Sarpatwari¹, Joan E Landon¹, Rishi J Desai²

Affiliations

¹ Brigham and Women's Hospital.
² Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

PMID: 31943866
DOI: 10.1002/art.41201

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antirheumatic Agents / economics
Antirheumatic Agents / therapeutic use*
Biosimilar Pharmaceuticals / economics
Biosimilar Pharmaceuticals / therapeutic use*
Health Care Costs / trends*
Humans
Infliximab / economics
Infliximab / therapeutic use*
Patient Acceptance of Health Care / statistics & numerical data*
Rheumatic Diseases / drug therapy*
Rheumatic Diseases / economics
Tumor Necrosis Factor Inhibitors / economics
Tumor Necrosis Factor Inhibitors / therapeutic use*
United States

Substances

Antirheumatic Agents
Biosimilar Pharmaceuticals
Tumor Necrosis Factor Inhibitors
Infliximab